Search

Introduction. Symptoms of COVID-19 disease can be identified within months and are observed in some cases as ongoing symptomatic COVID-19 (signs and symptoms 4–12 weeks after onset) or post-COVID-19 syndrome (> 12 weeks after onset). These symptoms are collectively referred to as long COVID-19. Long-term manifestations of COVID-19 occur in various organs, including fatigue, shortness of breath, and cognitive impairment. Little is known about the results of various examinations done on patients after COVID-19, such as MRI diagnostics or electroencephalography (EEG). The aim of our study was to identify markers that indicate cognitive impairment in patients with long COVID when conducting not only the traditional scale for assessing cognitive impairment (Montreal Cognitive Assessments test - MoCA test), but also other instrumental research methods. Methods. 70 patients with long COVID were prospectively assessed by scales and underwent instrumental methods of investigation (polysomnography, EEG, cervical ultrasound, CT and MRI brain perfusion). The cohort was divided into two groups depending on the severity of the course of the coronavirus infection: group A - mild and moderate severity (50 patients), and group B - severe condition (20 patients). Results. When comparing the results of cognitive screening in two groups, the MMSE scale and some characteristics of instrumental methods turned out to be statistically significant: polysomnography, ultrasound of the vessels of the neck. Conclusion. Although memory, as a complex of cognitive abilities and higher mental functions, has retained the functions of reproducing knowledge, but not of accumulating, for the application of skills and abilities. The violations were in terms of reducing the speed of information processing and memorization. But these changes correlate with Ipso facto age-related changes in patients than with coronavirus infection. [ABSTRACT FROM AUTHOR]

Aim. To study clinical, laboratory and psychological aspects of moderate coronavirus disease 2019 (COVID-19) in cardiovascular patients one month after discharge from the hospital.Material and methods. The study included 88 patients with cardiovascular diseases hospitalized for COVID-19. After 1 month, 72 respondents continued the participation in the study. Medical history collection, physical examination, and diagnostic investigations were performed. We used the Hospital Anxiety and Depression Scale (HADS) by Zigmond A. S., Snaith R. P., Beck Anxiety Inventory scale, Mini-mental State Examination (MMSE) scale for assessing mental status.Results. One month after discharge, there was a decrease in the number of patients with signs of impaired respiratory system, such as cough, shortness of breath, chest congestion, while a decrease in exercise tolerance persists was revealed in 80,5% (out of 95,5% during hospiatalization), generalized weakness and increased sweating — in 69,5%. In addition, 38,9% of patients noted a noticeable, newly reported, hair loss. Attention is drawn to the high prevalence of neurological symptoms during hospiatalization, including dizziness, severe headaches not relieved by analgesics and non-steroidal anti-inflammatory drugs, lethargy, disorientation of place and time, and in some cases even hallucinations. Some of the symptoms persist after 1 month: 55,5% note a decrease in memory, 36% — feelings of fear and anxiety, 63,9% — sleep disorders in the form of frequent nocturnal awakenings (19,4%), insomnia (16,6%), long falling asleep (11,1%). Some of the respondents revealed unfavorable events over the past month as follows: blood pressure (BP) destabilization in the form of episodes of BP increase and decrease during the day — 36,0%, hypertensive crisis — 14,0%. There was an increase in the number of patients with subclinical and clinical depression (p

The coronavirus disease 2019 (COVID-19) pandemic is associated with high virulence, mortality and healthcare burden around the world. One of its features is procoagulant activity, which leads to a high incidence of thromboembolic events in the lungs and other organs. Therefore, from the very onset of the moderate COVID-19, low molecular weight heparins began to be used as anticoagulants, which proved to have a beneficial effect on mortality and the disease course and were included in all guidelines. However, the question on anticoagulant therapy need after discharge from the hospital is controversial. The opinions of various medical professional communities on this issue are divided. In particular, some of them, including the Russian Ministry of Health guidelines recommend 30-45day anticoagulation using novel oral anticoagulants (dabigatran, rivaroxaban, apixaban), but other sources do not provide such recommendations. This review discusses the effectiveness of anticoagulant therapy after COVID-19, as well as the need to use stratification scales to assess this therapy.